Skip to main content

Drug Therapies

In the past decade alone, new drugs and new uses for existing drugs have greatly improved rates of cure or remission for patients of all ages. Newer "targeted therapies" and "risk-adapted therapies" have resulted in higher overall response rates and decreased side effects. More than 50 drugs of different types are now being used singularly or in combination to treat blood cancers.

Blood cancer treatment often includes one or a combination of:

Goal of Drug Therapy

The goal of drug therapy is to eliminate cancer cells so that:

  • There's no sign of illness
  • Normal cells are restored (remission)

Cancer cells can grow too fast or fail to die quickly. Drug therapy can speed up cancer cell death. 

Types Of Drug Therapies

Various types of anticancer medications kill cancer cells in different ways. The type of drug your doctor chooses to treat you can depend on your age, the type and stage of disease, your response to previous treatments and other factors.

Some blood cancers are treated effectively with a single drug. However, many conventional and investigational drug therapies combine drugs that attack cancer cells at different points in their growth cycles. This approach often makes therapy more effective and reduces the chance that the cancer cells will become resistant to a particular drug. As a result, more patients are achieving long-term remissions or cures.

Sometimes cancer cells may be resistant to the initial drugs used or can become resistant to the drugs after a period. In this case, your doctor may prescribe different drugs to target and kill the cancerous cells.

For information about specific drugs, visit Drug Listings.

Antimetabolites: Antimetabolites mimic the building blocks of DNA or RNA that cancer cells need to survive and grow. When the cancer cell uses an antimetabolite instead of the natural substances, it can't produce normal DNA or RNA and the cell dies.

Antimitotics: Antimitotics damage cancer cells by blocking a process called mitosis (cell division), which prevents cancer cells from dividing and multiplying.

Antitumor Antibiotics: Antitumor antibiotics prevent cell division by either binding to DNA to prevent the cells from duplicating or inhibiting RNA synthesis. 

Asparagine-Specific Enzymes: Some enzymes can prevent cancer cells from surviving. 

Bisphosphonates: Bisphosphonates are used to treat high levels of calcium in the blood caused by certain cancers, including myeloma. Bisphosphonates won't slow or stop the spread of cancer, but they can slow bone breakdown, increase bone thickness and reduce bone pain and fracture risk. 

Chemotherapy: Click here to read about chemotherapy.

DNA-Damaging Agents (Antineoplastics) and Alkylating Agents: DNA-damaging agents (antineoplastics) and alkylating agents react with DNA to change it chemically and keep it from allowing cell growth. 

DNA-Repair Enzyme Inhibitors: DNA-repair enzyme inhibitors attack the cancer cell proteins (enzymes) that normally repair damage to DNA. DNA repair is a normal and vital process within the cell. Without this repair process, the cancer cell is much more susceptible to damage and cannot grow. 

Histone Deacetylase Inhibitors: Histone deacetylase inhibitors attack cancer cells by targeting the proteins that support DNA in the cell nucleus. 

Hormones (Corticosteroids): Certain hormones (corticosteroids) can kill lymphocytes. They're believed to work by blocking cell metabolism through their effect on specific genes. In high doses, these synthetic hormones — relatives of the natural hormone cortisol — can kill malignant lymphocytes. 

Hypomethylating (Demethylating) Agents: Hypomethylating (demethylating) agents interfere with cancer cell duplication by slowing or reversing hypermethylation. Methylation is a critical part of cell growth and replication. This process sometimes speeds up in cancer cells. 

Immunomodulators: Immunomodulators influence the immune system function by suppressing or stimulating immune response. 

Janus-Associated Kinase (JAK) Inhibitors: JAK inhibitors block the enzymes JAK1, JAK2, JAK3 and tyrosine kinase 2, which play a role in the cell-signaling process that leads to the inflammatory and immune responses seen in certain diseases. JAK inhibitors interrupt the signaling pathway. 

Monoclonal Antibodies: Monoclonal antibodies are laboratory-produced proteins that target specific antigens on the cancer cell's surface to interfere with the cell's function and destroy it. Some monoclonal antibodies are combined with a toxin or radioactive substance. 

Phosphoinositide 3-kinase inhibitors (PI3K inhibitors): PI3K (phospho inositide 3 kinases) inhibitors are a group of closely related kinase proteins. They act like switches in the cell – turning on other proteins. Switching on PI3Ks may make cells grow and multiply, or trigger the development of blood vessels, or help cells to move around. In some cancers PI3K is permanently switched on, which means that the cancer cells grow uncontrollably. Researchers are developing new treatments that block (inhibit) PI3K. They hope this will stop the cancer cells growing and make them die. 

Proteasome Inhibitors: Proteasome inhibitors are designed to limit the effects of a cell structure called a proteasome. When a proteasome doesn't function properly, the cell dies. Cancer cells may be more susceptible to the effects of proteasome inhibition than normal cells. 

Selective Inhibitors of Nuclear Export (SINE): Compounds that block the export of tumor suppressor proteins so that they stay in the nucleus and stop tumor growth, leading to cell death.

Tyrosine Kinase Inhibitors: Tyrosine kinase inhibitors block the action of a specific, abnormal protein that gives cancer cells the signal to grow. 

 
 


To read about specific drugs, visit Drug Listings.


 

Blood Cancer United resources

Find free, specialized guidance and information for every type of blood cancer, request financial support, find emotional support, and connect with other members of the blood cancer community.

We are Blood Cancer United.

Everyone affected by blood cancer—patients, survivors, caregivers, researchers, advocates, fundraisers, everyone—has a story. Share yours.
A young child stands indoors on a hardwood floor wearing a lavender dress, colorful socks, and a pink head wrap. The portrait highlights a moment of confidence and individuality during a blood cancer experience, capturing the resilience of children and families navigating treatment, recovery, and survivorship. This image reflects hope, strength, and everyday life affected by pediatric blood cancer.

Kelly

Family member and caregiver

Close-up portrait of a blood cancer survivor standing along a coastal cliff at sunset, with the ocean and shoreline visible in the background. The individual wears a patterned head covering and a light-colored sweatshirt while looking toward the camera. Featured in a blood cancer survivor story, the image highlights resilience, hope, and finding moments of peace during and after blood cancer treatment. The scenic setting reflects strength, healing, and the support that helps people affected by leukemia, lymphoma, myeloma, and other blood cancers move forward.

Liz

acute myeloid leukemia (AML)

inspirational-stories-blood-cancer-shirley.jpeg

Shirley

large B-cell lymphoma (LBCL)

A selfie taken inside a vehicle shows a blood cancer survivor sitting beside a large brown dog wearing a harness and orange collar. The dog is positioned prominently in the foreground, while the individual wears sunglasses and a seatbelt. The candid photo highlights the comfort, companionship, and everyday moments that support many people affected by blood cancer during survivorship and recovery.

Kaitlyn

survivor

Two people wearing bright yellow banana costumes pose outdoors near an active volcanic eruption, with lava and a large plume of smoke rising in the background. The playful travel photo captures a memorable moment of adventure, humor, and connection. The image accompanies a blood cancer survivor story, reflecting resilience, celebrating life after a blood cancer diagnosis, and finding joy in meaningful experiences.

Thomas

acute lymphoblastic leukemia (ALL)

Portrait of a blood cancer advocate standing in front of a red Leukemia & Lymphoma Society event backdrop, wearing a wide-brimmed hat, glasses, and a patterned top. The image highlights community engagement, blood cancer awareness, and support for patients, survivors, and families affected by leukemia, lymphoma, myeloma, and other blood cancers. Featured as part of a blood cancer survivor story, the photo reflects advocacy, resilience, and the impact of collective action in the blood cancer community.

Angie

Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

A blood cancer volunteer stands with a bicycle at Mount Rushmore National Memorial, with the iconic mountain monument and visitors visible in the background. Wearing cycling gear and protective arm sleeves, the individual poses during a long-distance cycling adventure that supports blood cancer awareness and advocacy. Featured in a blood cancer survivor story, the image highlights resilience, perseverance, and life beyond a blood cancer diagnosis while inspiring hope for others affected by leukemia, lymphoma, myeloma, and other blood cancers.

Darin

Volunteer and supporter

A person is lying in a hospital bed wearing a patterned hospital gown. The individual has multiple hospital wristbands on one arm and a small bandage near the wrist. They are holding a light blue surgical mask near their chin. The background shows a curtain with a circular pattern and part of a wall-mounted medical device.

Georgia

mixed phenotype acute leukemia (MPAL)

Close-up indoor portrait of a blood cancer survivor wearing a burgundy polka-dot blouse, illuminated by natural window light. The image accompanies a blood cancer survivor story, highlighting resilience, advocacy, and life after a blood cancer diagnosis. This authentic portrait reflects the strength of individuals affected by leukemia, lymphoma, myeloma, and other blood cancers, while emphasizing hope, survivorship, and the importance of support within the blood cancer community.

Anna

mantle cell lymphoma (MCL)

Outdoor portrait of a blood cancer survivor standing on a sidewalk in a landscaped neighborhood, wearing a black top and a colorful statement necklace. Trees and greenery create a natural backdrop. Featured in a blood cancer survivor story, the image highlights resilience, hope, and life beyond a blood cancer diagnosis. The photo represents the strength of individuals affected by leukemia, lymphoma, myeloma, and other blood cancers, while emphasizing the importance of awareness, support, and survivorship.

Sharon

non-Hodgkin lymphoma (NHL)

Close-up indoor selfie showing an older adult wearing glasses and a red shirt while holding a baby. Soft natural light fills the room, highlighting a meaningful family moment across generations. Featured in a blood cancer survivor story, the image reflects the importance of family, resilience, and celebrating everyday milestones after a blood cancer diagnosis. The photo represents hope, connection, and the support that helps individuals and families navigate the blood cancer experience.

Joseph

plasma cell leukemia (PCL)

Portrait of a blood cancer advocate standing in front of a green floral background featuring a white dove graphic. The individual wears glasses and a sleeveless top while posing for the camera. Featured as part of a blood cancer survivor story, the image highlights awareness, remembrance, resilience, and community support for people affected by leukemia, lymphoma, myeloma, and other blood cancers. The photo reflects hope and the lasting impact of blood cancer advocacy and patient storytelling.

Joan

Family member and supporter

The Leukemia & Lymphoma Society (LLS) is now Blood Cancer United. Learn more.